Towards validated assays for key immunological outcomes in malaria vaccine development

Vaccine

Volumn 29, Issue 17, 2011, Pages 3093-3095

  Cavanagh, David R ^b   Dubois, Patrice M ^c   Holtel, Andreas ^d   Kisser, Agnes ^e   Leroy, Odile ^e   Locke, Emily ^f   Moorthy, Vasee S ^g   Remarque, Edmond J ^h   Shi, Ya Ping ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Immunovacc Consulting   (Belgium)

^c EUROPEAN COMMISSION   (Belgium)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e PATH Malaria Vaccine Initiative   (United States)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

DRUG DETERMINATION; IMMUNOGENICITY; IMMUNOLOGY; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STANDARDIZATION; VALIDATION PROCESS;

BIOLOGICAL MARKERS; HEALTH SERVICES RESEARCH; HUMANS; MALARIA; MALARIA VACCINES;

EID: 79954579951     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.070     Document Type: Letter

References (6)

1. Malaria Vaccine Technology Roadmap Final Report. 2006.
2. WHO Initiative for Vaccine Research list of clinical and pre-clinical malaria vaccine projects. [cited; Available from: ]. http://www.who.int/vaccine_research/en/Rainbow/index.html.
3. PATH MVI's Focus on Evaluation Technologies. [cited; Available from: ]. http://www.malariavaccine.org/rd-eval-tech.php.
4. Reed Z.H., Kieny M.P., Engers H., Friede M., Chang S., Longacre S., et al. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. Vaccine 2009, 27(March 4 (10)):1651-1660.
5. Arnot D.E., Cavanagh D.R., Remarque E.J., Creasey A.M., Sowa M.P., Morgan W.D., et al. Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum. Clin Vaccine Immunol 2008, 15(September (9)):1345-1355.
6. Galamo C.D., Jafarshad A., Blanc C., Druilhe P. Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition. J Infect Dis 2009, 199(April 15 (8)):1151-1154.